CEP-9722

Cat. No.:	HY-105303
CAS No.:	916574-83-9
Molecular Formula:	$C_{24}H_{26}N_4O_3$
Molecular Weight:	418.49
Target:	PARP
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CEP-9722, the proagent of CEP-8983, is a selective and orally active PARP-1 and PARP-2 inhibitor with IC_{50}s of 20 nM and 6 nM, respectively. CEP-9722 has anticancer effects[1][2].	
IC_{50} & Target	PARP-1 20 nM (IC_{50})	PARP-2 6 nM (IC_{50})

In Vivo

CEP-9722 (100-200 mg/kg/day; oral gavage; once daily; for 5 days a week for 4 weeks) shows dose-dependent antitumor activity in RT4 xenografts; 200 mg/kg daily is better than control and 100 mg/kg is not[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice bearing subcutaneous RT4 human urothelial carcinoma (UC) tumors[1]
Dosage:	100 or 200 mg/kg/day
Administration:	Oral gavage; once daily; for 5 days a week for 4 weeks
Result:	Showed dose-dependent antitumor activity in RT4 xenografts.

REFERENCES

[1]. Weiguo Jian, et al. Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage. Anticancer Drugs. 2014 Sep;25(8):878-86.

[2]. Ruth Plummer, et al. Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer Chemother Pharmacol. 2014 Aug;74(2):257-65.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA